Olutasidenib alone or with azacitidine in IDH1-mutated acute myeloid leukaemia and myelodysplastic syndrome: phase 1 results of a phase 1/2 trialJustin M. Watts, Jörge E. Cortes, Sang‐Min Lee et al.|The Lancet Haematology|2022Cited by 118
Olutasidenib (FT-2102), an IDH1m Inhibitor As a Single Agent or in Combination with Azacitidine, Induces Deep Clinical Responses with Mutation Clearance in Patients with Acute Myeloid Leukemia Treated in a Phase 1 Dose Escalation and Expansion StudyJustin M. Watts, Jörge E. Cortes, Maria R. Baer et al.|Blood|2019Cited by 26